Form 4: PMV Pharmaceuticals Director Option Grant and Transfer

Director Carol Giltner Gallagher received a stock option grant and subsequently transferred the holdings to a revocable trust.

Summary

• Director Carol Giltner Gallagher was granted 42,000 stock options with an exercise price of $1.19 on June 4, 2026.
• The options vest on the earlier of June 4, 2027, or the date of the next annual stockholders meeting.
• Following the grant, the director transferred the 42,000 options to The Gallagher Revocable Trust, for which she serves as trustee.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation and internal asset management.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• The value of the options is dependent on the future market performance of PMVP common stock relative to the $1.19 exercise price.

Future Outlook

The options are set to vest in one year, contingent upon the director's continued service or the occurrence of the next annual meeting.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation and estate planning, common in the biotechnology sector to ensure board alignment with corporate milestones.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard practice for small-cap biotechnology firms to preserve cash while incentivizing board members.

Related Party Transactions

• Transfer of 42,000 stock options to The Gallagher Revocable Trust, an entity controlled by the reporting person.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard director equity compensation.

Next Steps

• Vesting of options on June 4, 2027, or the date of the next annual meeting.

Key Dates

Keywords

PMVP, PMV Pharmaceuticals, Form 4, Insider Trading, Stock Options, Director Compensation